EMBC Healthcare

Embecta Corp.

$6.08-1.78%

Price as of close on Nov 3, 2026 · Financials updated Oct 8, 2026

Basics

Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States
Market cap: 344.5M USD
Enterprise value: 1.6B USD
Full-time employees: 1,850

Overall health

Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.68 vs a peer median of 2.59)higher risk: less liquidity (current ratio 1.68 vs peers 2.59)

Ranks #523 of 1,157 healthcare companies (top 46%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
Embecta's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Valuation signals disagree. Cheaper than 95% of peers on earnings, but only 50% on free cash flow.
Relative to its earnings, Embecta looks cheaper than 95% of peers; relative to its free cash flow, cheaper than only 50%. The valuation score blends the two, so look at which measure fits this business best.
Profitable, but revenue is shrinking. More profitable than most peers, but revenue fell 7.6% in the 12 months to June 2026 vs the 12 months before.
Embecta is more profitable than most peers, yet revenue fell 7.6% in the 12 months to June 2026 vs the 12 months before.
Profit is backed by cash. Free cash flow is 188% of reported profit.
Embecta's free cash flow is 188% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

StockQuotient Score

54/ 100

Oct 5 54 → Nov 4 54

Valuation

Is the price right?

95/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Share count down 4.5%

Valuation also moves with the share price every day.

Why

Stronger than most peers on:

▲ Earnings yield
▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield25.4%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile30% base weight · Z-score 6.11Sector median: 0.0148 · MAD: 0.0148

EBITDA yield16.9%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 3.21Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield47.8%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingOutlier capped at sector 5th/95th percentile20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-177.9%

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

24/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

12-month revenue fell 2.3%

Why

Weaker than most peers on:

▼ Revenue growth
▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth8.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.06Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth-2.9%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -1.04Sector median: 0.0584 · MAD: 0.0840

Revenue growth-7.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.41Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

90/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Operating margin fell 3.8 points to 21.9%

Why

Stronger than most peers on:

▲ ROIC
▲ Operating margin
▲ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin21.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.22Sector median: 0.0706 · MAD: 0.1217

Return on assets6.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.98Sector median: 0.0166 · MAD: 0.0537

Return on invested capital28.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 2.33Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin59.0%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equityUnavailable

Missing · left out of the scoreInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity
▼ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.83

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.61Sector median: 0.6250 · MAD: 0.3380

Current ratio1.68×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.65Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Embecta

Is Embecta getting weaker?: Its latest SEC filing (Aug 7, 2026) was mixed: some things better, some worse: operating margin fell 3.8 points to 21.9%; 12-month revenue fell 2.3%. Its overall score is unchanged at 54/100 since Oct 28, 2026.
How is Embecta valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 95/100 against 1,393 healthcare peers. Earnings yield 25.4% vs a peer median of 1.5% (stronger than 95% of peers).Earnings yield 25.4% vs peers 1.5% (stronger than 95% of peers).
Is Embecta growing?: More slowly than most of its peers. Growth scores 24/100 against 1,393 healthcare peers. Revenue growth -7.6% vs a peer median of 6.1% (weaker than 82% of peers).Revenue growth -7.6% vs peers 6.1% (weaker than 82% of peers).
How profitable is Embecta?: More profitable than most of its peers. Profitability scores 90/100 against 1,393 healthcare peers. Return on invested capital 28.1% vs a peer median of 4.7% (stronger than 92% of peers).Return on invested capital 28.1% vs peers 4.7% (stronger than 92% of peers).
How risky is Embecta?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.68× vs a peer median of 2.59× (weaker than 68% of peers).Current ratio 1.68× vs peers 2.59× (weaker than 68% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 7, 2026 · compared with the quarter ended Mar 31, 2026

Mixed: some things better, some worse

Operating margin fell 3.8 points to 21.9%
12-month revenue fell 2.3%
Share count down 4.5%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	1.0B USD	1.0B USD	−2.3%
Net income (12 months)	111.9M USD	87.5M USD	−21.8%
Operating margin	25.8%	21.9%	−3.8 pts
Free cash flow (12 months)	204.7M USD	164.6M USD	−19.6%
Debt	1.3B USD	1.5B USD	+9.7%
Cash	184.9M USD	214.7M USD	+16.1%
Shares outstanding	59.3M	56.7M	−4.5%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Instruments & Supplies · 25 companies

Valuations in Medical Instruments & Supplies are near the bottom of their range since Jul 2018.

18% of months since Jul 2018 were valued lower than now.
0% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +17% vs the whole market, against a usual +86%.

Jul 2018Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Sep 2021	FY Sep 2022	FY Sep 2023	FY Sep 2024	FY Sep 2025	Change
Gross margin	68.7%	68.6%	66.9%	65.5%	62.6%	▼ 2.8 pts
Operating margin	42.2%	27.4%	19.8%	14.9%	22.4%	▲ 7.6 pts
Net margin	35.6%	19.8%	6.3%	7.0%	8.8%	▲ 1.9 pts
Return on assets (ROA)	52.6%	20.6%	5.8%	6.1%	8.7%	▲ 2.7 pts
Return on equity (ROE)	69.8%	—	—	—	—	—
Free cash flow margin	36.0%	34.4%	3.7%	1.8%	16.9%	▲ 15 pts
Current ratio	1.78×	2.21×	2.12×	2.03×	2.41×	▲ 19%
Quick ratio	1.06×	1.80×	1.69×	1.58×	1.73×	▲ 9.9%
Debt to equity	0.00×	—	—	—	—	—

EMBC price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.68 vs a peer median of 2.59)higher risk: less liquidity (current ratio 1.68 vs peers 2.59)

Ranks #523 of 1,157 healthcare companies (top 46%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

Embecta's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Valuation signals disagree. Cheaper than 95% of peers on earnings, but only 50% on free cash flow.

Relative to its earnings, Embecta looks cheaper than 95% of peers; relative to its free cash flow, cheaper than only 50%. The valuation score blends the two, so look at which measure fits this business best.

Profitable, but revenue is shrinking. More profitable than most peers, but revenue fell 7.6% in the 12 months to June 2026 vs the 12 months before.

Embecta is more profitable than most peers, yet revenue fell 7.6% in the 12 months to June 2026 vs the 12 months before.

Profit is backed by cash. Free cash flow is 188% of reported profit.

Embecta's free cash flow is 188% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Questions investors ask about Embecta

Is Embecta getting weaker?

Its latest SEC filing (Aug 7, 2026) was mixed: some things better, some worse: operating margin fell 3.8 points to 21.9%; 12-month revenue fell 2.3%. Its overall score is unchanged at 54/100 since Oct 28, 2026.

How is Embecta valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 95/100 against 1,393 healthcare peers. Earnings yield 25.4% vs a peer median of 1.5% (stronger than 95% of peers).Earnings yield 25.4% vs peers 1.5% (stronger than 95% of peers).

Is Embecta growing?

More slowly than most of its peers. Growth scores 24/100 against 1,393 healthcare peers. Revenue growth -7.6% vs a peer median of 6.1% (weaker than 82% of peers).Revenue growth -7.6% vs peers 6.1% (weaker than 82% of peers).

How profitable is Embecta?

More profitable than most of its peers. Profitability scores 90/100 against 1,393 healthcare peers. Return on invested capital 28.1% vs a peer median of 4.7% (stronger than 92% of peers).Return on invested capital 28.1% vs peers 4.7% (stronger than 92% of peers).

How risky is Embecta?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.68× vs a peer median of 2.59× (weaker than 68% of peers).Current ratio 1.68× vs peers 2.59× (weaker than 68% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

1.0B USD

1.0B USD

−2.3%

Net income (12 months)

111.9M USD

87.5M USD

−21.8%

Operating margin

25.8%

21.9%

−3.8 pts

Free cash flow (12 months)

204.7M USD

164.6M USD

−19.6%

Debt

1.3B USD

1.5B USD

+9.7%

Cash

184.9M USD

214.7M USD

+16.1%

Shares outstanding

59.3M

56.7M

−4.5%

Key ratios

FY Sep 2021

FY Sep 2022

FY Sep 2023

FY Sep 2024

FY Sep 2025

Change

Gross margin

68.7%

68.6%

66.9%

65.5%

62.6%

▼ 2.8 pts

Operating margin

42.2%

27.4%

19.8%

14.9%

22.4%

▲ 7.6 pts

Net margin

35.6%

19.8%

6.3%

7.0%

8.8%

▲ 1.9 pts

Return on assets (ROA)

52.6%

20.6%

5.8%

6.1%

8.7%

▲ 2.7 pts

Return on equity (ROE)

69.8%

—

Free cash flow margin

36.0%

34.4%

3.7%

1.8%

16.9%

▲ 15 pts

Current ratio

1.78×

2.21×

2.12×

2.03×

2.41×

▲ 19%

Quick ratio

1.06×

1.80×

1.69×

1.58×

1.73×

▲ 9.9%

Debt to equity

0.00×

—